DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain

Not Applicable

Terminated

Conditions: Meningitis

Interventions: Drug: 1% lidocaine
Drug: topical lidocaine

First Posted Date: 2012-05-25

Last Posted Date: 2016-12-13

Lead Sponsor: Georgetown University

Target Recruit Count: 5

Registration Number: NCT01606150

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV

Phase 1

Completed

Conditions: Tobacco Cessation
Tobacco Use Cessation
Tobacco Use Disorder
Tobacco-Use Disorder
Tobacco Dependence
Virus, Human Immunodeficiency

Interventions: Behavioral: Web-Based Tailored Smoking Cessation Intervention
Behavioral: Standard of Care

First Posted Date: 2012-04-04

Last Posted Date: 2014-05-12

Lead Sponsor: Georgetown University

Target Recruit Count: 138

Registration Number: NCT01570595

Locations: 🇺🇸
Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States

ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

Not Applicable

Terminated

Conditions: Chronic Venous Hypertension With Ulcer

Interventions: Device: ActiVAC System
Other: Compression therapy

First Posted Date: 2012-02-08

Last Posted Date: 2020-03-19

Lead Sponsor: Georgetown University

Target Recruit Count: 2

Registration Number: NCT01528293

Locations: 🇺🇸
Georgetown University Hospital, Center for Wound Healing, Washington, District of Columbia, United States

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Phase 1

Conditions: Advanced Solid Tumor Malignancies

Interventions: Drug: PD-0332991
Drug: 5-FU
Drug: Oxaliplatin

First Posted Date: 2012-02-01

Last Posted Date: 2020-03-04

Lead Sponsor: Georgetown University

Target Recruit Count: 37

Registration Number: NCT01522989

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

Not Applicable

Completed

Conditions: Peripheral Vascular Disease

Interventions: Device: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Device: SPY Imaging

First Posted Date: 2012-01-31

Last Posted Date: 2020-03-11

Lead Sponsor: Georgetown University

Target Recruit Count: 31

Registration Number: NCT01522495

Locations: 🇺🇸
Georgetown University Medical Center; Center for Wound Healing, Washington, District of Columbia, United States

Phase I Study of CS-7017 and Bexarotene

Phase 1

Terminated

Conditions: Lymphoma
Solid Tumors
Multiple Myeloma

Interventions: Drug: CS-7017 and Bexarotene

First Posted Date: 2012-01-05

Last Posted Date: 2017-02-14

Lead Sponsor: Georgetown University

Target Recruit Count: 9

Registration Number: NCT01504490

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Panitumumab and bortezomib

First Posted Date: 2012-01-05

Last Posted Date: 2020-03-16

Lead Sponsor: Georgetown University

Target Recruit Count: 6

Registration Number: NCT01504477

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline/Placebo
Drug: Rasagiline

First Posted Date: 2011-12-22

Last Posted Date: 2015-12-16

Lead Sponsor: Georgetown University

Target Recruit Count: 34

Registration Number: NCT01497652

Locations: 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

Lapatinib and Bortezomib in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Lapatinib and bortezomib

First Posted Date: 2011-12-22

Last Posted Date: 2016-02-17

Lead Sponsor: Georgetown University

Target Recruit Count: 15

Registration Number: NCT01497626

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Phase 1

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: ABT-888 and mFOLFOX-6

First Posted Date: 2011-12-12

Last Posted Date: 2020-03-03

Lead Sponsor: Georgetown University

Target Recruit Count: 64

Registration Number: NCT01489865

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy